Administered in two doses three weeks apart, the Novavax vaccine is based on a more traditional technique than messenger RNA.
The United States Medicines Agency on Wednesday authorized the vaccine against Novavax COVID-19 vaccine for adults 18 and older, thus providing an additional option to get vaccinated in the United States in hopes of helping convince the reluctant.
The vaccine produced by this American company is already available in dozens of other countries.
In the United States, on the other hand, only three anti-COVID vaccines were authorized for the moment: those with messenger RNA from Pfizer and Moderna as well as that from Johnson & Johnson. However, access to the latter has been limited due to an increased risk of serious thrombosis.
Novavax's emergency vaccine authorization will provide another option for American adults who have not yet received a COVID-19 vaccine, Robert Califf said in a statement. , the boss of the drug agency (FDA).
Administered in two doses three weeks apart, it is based on a more classic technique than the #x27;messenger RNA, which has been the target of many conspiracy theories, although it has been shown to be very safe.
The Novavax vaccine contains a component of the virus that triggers an immune response, similar to pertussis, meningococcal meningitis and hepatitis B vaccines. of people in the United States and Mexico, it has been shown to be 90% effective against symptomatic cases of COVID-19. However, this figure must be put into perspective, as these trials were conducted before the Delta and Omicron variants.
Americans can be confident that this vaccine, like all other vaccines used in United States, has been subjected to the rigorous and comprehensive scientific analysis of the FDA, underlined Peter Marks, official within the agency.
The rate vaccination of the adult population is stagnating around 77% in the United States.
The US government announced this week that it had purchased 3.2 million doses of the Novavax vaccine in anticipation of the FDA decision.